Executive record

Susan L. Kelley, M.D.

Director at Dare Bioscience, Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:susan-l-kelley-m-dVersion: public-0As of: 2026-09-28

Not yet claimed7 published Claims3 sources
  • Director

Key Claims

Biography

Dr. Kelley has over 35 years of experience developing drugs in oncology and immunology. She currently serves on boards of IDEAYA Biosciences and A2 Biotherapeutics, and previously served on boards of Deciphera Pharmaceuticals, ArQule, and Immune Design Corp. She held senior positions at Bayer Healthcare and Bristol-Myers Squibb, and served as Chief Medical Officer of the Multiple Myeloma Research Consortium.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. DARE DEF 14A director slate

    sec filing · Source published: Apr 24, 2025 · Retrieved: May 15, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Board role: Board role: Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Nominating/Governance · Claim reviewed: May 15, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 15, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 15, 2026

  2. Open source

    sec proxy · Source published: Apr 24, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Dare Bioscience, Inc. · Claim reviewed: May 15, 2026

  3. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Dare Bioscience, Inc. · Claim reviewed: May 15, 2026